Viral suppression following switch to second-line antiretroviral therapy: Associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch

Journal of Infectious Diseases

Volumn 209, Issue 5, 2014, Pages 711-720

  Johnston, Victoria ^a   Cohen, Karen ^b   Wiesner, Lubbe ^b   Morris, Lynn ^c   Ledwaba, Johanna ^c   Fielding, Katherine L ^a   Charalambous, Salome ^d   Churchyard, Gavin ^a,d,e   Phillips, Andrew ^f   Grant, Alison D ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d AURUM INSTITUTE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adherence; resistance; second line antiretroviral therapy; virological failure

Indexed keywords

ADHERENCE; RESISTANCE; SECOND-LINE ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 84894282743     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit411     Document Type: Article

References (49)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. http://www.who.int/hiv/pub/arv/adult2010/en/. Accessed 15 September 2012.
2. Southern African HIV Clinicians Society. Guidelines for antiretroviral therapy in adults. www.sahivsoc.org. Accessed 15 September 2012.
3. National Department of Health, South Africa. Clinical guidelines for the management of HIV and AIDS in adults and adolescents. http ://www.fidssa.co.za/ Guidelines/2010-Adult-ART-Guidelines.pdf. Accessed 15 September 2012.
4. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012; 26:929-38.
5. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-6.
6. May Myat W, Maek ANW, Phonrat B, Kiertiburanakul S, Sungkanuparph S. Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. J Int Assoc Physicians AIDS Care (Chic) 2011; 10:57-63.
7. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012; 61:158-63.
8. Johnston V, Fielding K, Charalambous S, et al. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One 2012; 7:e36997.
9. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr 2012; 61:370-80.
10. Fox MP, Cutsem GV, Giddy J, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012; 60:428-37.
11. Fox MP, Shearer K, Maskew M, et al. Treatment outcomes after 7 years of public-sector HIV treatment. AIDS 2012; 26:1823-8.
12. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200:687-97.
13. Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 2012; 17:377-86.
14. Sigaloff KC, Ramatsebe T, Viana R,Wit TF,Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing firstline antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses 2011; 28:171-5.
15. Estill J, Egger M, Johnson LF, et al. Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One 2013; 8:e57611.
16. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis 2012; 205:1739-44.
17. Fox Z, Dragsted UB, Gerstoft J, et al. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther 2006; 11:761-70.
18. Gianotti N, Galli L, Boeri E, et al. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected patients. New Microbiol 2005; 28:319-26.
19. Trignetti M, Sing T, Svicher V, et al. Dynamics of NRTI resistance mutations during therapy interruption. AIDS Res Hum Retroviruses 2009; 25:57-64.
20. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. J Acquir Immune Defic Syndr 2008; 48:216-9.
21. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 2005; 19:1243-9.
22. Murri R, Ammassari A, Trotta MP, et al. Patient-reported and physicianestimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen InternMed 2004; 19:1104-10.
23. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817-33.
24. Liechty CA, Alexander CS, Harrigan PR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 2004; 18:127-9.
25. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-47.
26. Innes C, Hamilton R, Hoffmann CJ, et al. A novel HIV treatment model using private practitioners in South Africa. Sex Transm Infect 2012; 88:136-40.
27. Charalambous S, Grant AD, Day JH, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007; 19: 34-41.
28. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13(suppl 2):101-7.
29. Johnson VA, Calvez V, Gunthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19:156-64.
30. la Porte CJL, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3:4-14.
31. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48:176-82.
32. Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 2012; 56:1427-33.
33. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-6.
34. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving secondline HIV therapy in resource-limited countries. JAMA 2010; 304:303-12.
35. Lodwick R, Costagliola D, Reiss P, et al. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010; 170:410-9.
36. Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med 2010; 11:216-24.
37. Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIVpositive adults treated in rural northwestern Uganda. BMC Infect Dis 2009; 9:81.
38. van Oosterhout JJ, Bodasing N, Kumwenda JJ, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-70.
39. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007; 21:2293-301.
40. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep 2010; 7:44-51.
41. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637-46.
42. StohrW, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13:675-85.
43. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008; 61:389-93.
44. Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011; 16:527-34.
45. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 2010; 85:59-74.
46. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011; 56:333-9.
47. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a crosssectional study in Soweto, South Africa. AIDS 2010; 24:1679-87.
48. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012; 7: e32144.
49. Dahab M, Charalambous S, Karstaedt AS, et al. Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. BMC Public Health 2010; 10:430.